OVERVIEW
Onconova Therapeutics® Inc. is a private biopharmaceutical company developing new drugs for treatment of cancer and radiation injury. The company has advanced its lead product, rigosertib to a pivotal Phase III trial. Two other products are in early clinical development and 7 other products are in preclinical development.
HIGHLIGHTS
Rigosertib (Estybon® ON 01910.Na) is a Phase III stage targeted anticancer drug for blood cancers and solid tumors.
Ex-RAD® is a radiation countermeasure in development for use in both pre-exposure (prophylactic) and post-exposure (mitigation) scenarios.
UPCOMING EVENTS
BIO-Europe
Spring 2012
March 19th-21, 2012
Amsterdam, The Netherlands
ASCO
June 1-5, 2012
McCormick Place
Chicago, IL